Clinical trials: Clinical Trial, Phase I
Myelodysplastic Syndrome
Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
This is an extension study to investigate long term safety and efficacy of SyB C-1101 when orally administered every 3 weeks, twice daily for 14 consecutive days to the patients who have completed 6 cycles in the study 2012002…
- Trial name
- NCT02002936
- Testing
- SyB C-1101
- Where
- 4 sites in Japan
- Volunteers
- 1 people
- Sponsor
- SymBio Pharmaceuticals
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
This phase I/Ib trial studies the side effects and best dose of pembrolizumab when given together with afatinib dimaleate in treating patients with non-small cell lung cancer that has spread to other places in the body and…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02364609
- Testing
- Afatinib Dimaleate, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonathan Riess
Breast Cancer
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
The goals of this clinical research study are to learn the tolerable and effective doses of the drug MK-0646 that can be given in combination with Sprycel (dasatinib) and Faslodex (fulvestrant) to patients with hormone…
- Trial name
- NCT00903006
- Testing
- Fulvestrant, MK-0646, Dasatinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms
Dose Finding Study of BI 836880 in Patients With Solid Tumors
This is a Phase I, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously. The eligible patient population will be patients with advanced solid tumours.
- Trial name
- NCT02674152
- Testing
- BI 836880
- Where
- 3 sites in France, Germany
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Hantavirus Pulmonary Infection, Immunisation
Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device
This is a Phase 1, randomized, placebo controlled, double-blind, dose escalation trial of 48 males and non-pregnant females, 18-49 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03682107
- Testing
- Andes virus DNA vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs
The investigational therapy under study in this trial, regulatory T cells (Tregs), offers the hope of stabilizing further destruction of insulin producing beta cells in type 1 diabetes.
- Trial name
- Treg (NCT01210664)
- Testing
- Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Pancreatic Cancer
Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of Avastin and Tarceva in patients undergoing radiation therapy for carcinoma of the pancreas.
- Trial name
- TART (NCT00735306)
- Testing
- Avastin, Tarceva, Radiation Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Duke University
Prostate Cancer
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
The purpose of this research study is to determine the safety of giving ketoconazole, hydrocortisone and dutasteride (KHAD) with lapatinib.
- Trial name
- KHLAD (NCT00953576)
- Testing
- ketoconazole, hydrocortisone, dutasteride
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Dengue
Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine
The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.
- Trial name
- NCT00290147
- Testing
- D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Healthy
Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male
To confirm the PK similarity of IBI305 and bevacizumab in healthy volunteers .
- Trial name
- NCT03083990
- Testing
- IBI305(Bevacizumab Biosimilar), Avastin(Bevacizumab)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Sarcoma
Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
The purpose of this study is to identify a safe dosing regimen for the combination of Torisel and liposomal doxorubicin in patients with recurrent sarcoma.
- Trial name
- NCT00949325
- Testing
- temsirolimus plus liposomal doxorubicin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer, Pancreas Neoplasms
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death in the United States, and no combination therapy is far superior to gemcitabine alone.
- Trial name
- NCT00683085
- Testing
- HLA-A*02:01-restricted VEGFR1-derived peptide vaccination
- Where
- Japan
- Volunteers
- 2 people
- Sponsor
- Tokyo University
Breast Cancer, Breast Cancer, Male
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
This purpose of this study is to evaluate the safety and to find the optimal dose in participants with human epidermal growth factor receptor 2 (HER2) positive breast cancer who are given the combination of Interferon-gamma with…
- Conditions
- Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
- Trial name
- NCT03112590
- Testing
- Interferon-gamma (IFN-γ), Paclitaxel, Trastuzumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Neoplasms
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
The purpose of the study is to address the following hypotheses: (i) Anti-PD-L1 therapy with MEDI4736 administered concomitantly with weekly nab-paclitaxel followed by MEDI4736 concomitant with ddAC neoadjuvant chemotherapy will…
- Trial name
- NCT02489448
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Yale University
End Stage Renal Disease (ESRD)
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation
In this Phase I/II trial, 10 highly sensitized patients will be entered after informed consent and will receive Intravenous Immunoglobulin (IVIG) at 2 gm/kg + Tocilizumab 8 mg/kg x 5 doses on days 15, 45, 75, 105, 119, 135, and…
- Trial name
- NCT01594424
- Testing
- Tocilizumab, Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cedars-Sinai Medical Center
Leukemia
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.
- Trial name
- CLL-8 (NCT00281918)
- Testing
- Rituximab, Cyclophosphamide, Fludarabine Phosphate
- Where
- 162 sites in Australia, Austria and 9 more
- Volunteers
- 817 people
- Sponsor
- Hoffmann-La Roche
Sarcoma
A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
The purpose of this research study is to find out more information such as: to determine the effects of high and low fat foods on the pharmacokinetics (PK) of oral KPT-330 tablets and to compare PK of capsules and tablets in Arms…
- Trial name
- NCT01896505
- Testing
- KCP-330
- Where
- 2 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Karyopharm Therapeutics Inc
Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III
The purpose of this study is to identify the maximum tolerated dosage of sodium phenylbutyrate in children with spinal muscular atrophy types II or III; and to determine if the drug has an effect on SMN mRNA and protein levels.
- Trial name
- NPTUNE01 (NCT00439569)
- Testing
- sodium phenylbutyrate
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Westat
Precancerous Condition, Stage 0 Melanoma
Lovastatin in Treating Patients At High Risk of Melanoma
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma.
- Conditions
- Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
- Trial name
- NCT00462280
- Testing
- lovastatin, biopsy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT04037254
- Testing
- Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib
- Where
- 95 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- NRG Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.